Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee

详细信息    查看全文

• 作者：Jeanne Palmer¹ ; ^{Palmer.Jeanne@mayo.edu" class="auth_mail" title="E-mail the corresponding author} ; Jeannine S. McCune² ; ^{jmccune@u.washington.edu" class="auth_mail" title="E-mail the corresponding author} ; Miguel-Angel Perales³ ; David Marks⁴ ; Joseph Bubalo⁵ ; Mohamad Mohty⁶ ; John R. Wingard⁷ ; Angelo Paci⁸ ; Moustapha Hassan⁹ ; Christopher Bredeson¹⁰ ; Joseph Pidala¹¹ ; Nina Shah¹² ; Paul Shaughnessy¹³ ; Navneet Majhail¹⁴ ; Jeff Schriber¹⁵ ; Bipin N. Savani¹⁶ ; Paul A. Carpenter¹⁷
• 关键词：Hematopoietic cell transplantation ; Busulfan ; Precision medicine ; Pharmacokinetics ; Therapeutic drug monitoring
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：22
• 期：11
• 页码：1915-1925
• 全文大小：443 K

文摘

The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This “Considerations” document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians.